Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute.
Chihara D, Huang EP, Finnigan SR, Cordes LM, Skorupan N, Fukuda Y, Rubinstein LV, Ivy SP, Doroshow JH, Nastoupil LJ, Flowers CR, Takebe N. Chihara D, et al. Among authors: huang ep. J Clin Oncol. 2022 Jun 10;40(17):1949-1957. doi: 10.1200/JCO.21.02190. Epub 2022 Mar 9. J Clin Oncol. 2022. PMID: 35263120 Free PMC article. Clinical Trial.
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, Reeves S, Ellis LM, Sargent DJ, Rosner GL, LeBlanc ML, Ratain MJ. Paller CJ, et al. Clin Cancer Res. 2014 Aug 15;20(16):4210-7. doi: 10.1158/1078-0432.CCR-14-0521. Clin Cancer Res. 2014. PMID: 25125258 Free PMC article. Review.
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.
Litière S, Isaac G, De Vries EGE, Bogaerts J, Chen A, Dancey J, Ford R, Gwyther S, Hoekstra O, Huang E, Lin N, Liu Y, Mandrekar S, Schwartz LH, Shankar L, Therasse P, Seymour L; RECIST Working Group. Litière S, et al. J Clin Oncol. 2019 May 1;37(13):1102-1110. doi: 10.1200/JCO.18.01100. Epub 2019 Mar 12. J Clin Oncol. 2019. PMID: 30860949 Free PMC article.
Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials.
Paller CJ, Huang EP, Luechtefeld T, Massett HA, Williams CC, Zhao J, Gravell AE, Tamashiro T, Reeves SA, Rosner GL, Carducci MA, Rubinstein L, Ivy SP. Paller CJ, et al. Among authors: huang ep. Front Med (Lausanne). 2019 Jun 4;6:122. doi: 10.3389/fmed.2019.00122. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31214592 Free PMC article.
A Phase 1 Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy.
Patel KR, Rydzewski NR, Schott E, Cooley-Zgela T, Ning H, Cheng J, Salerno K, Huang EP, Lindenberg L, Mena E, Choyke P, Turkbey B, Citrin DE. Patel KR, et al. Among authors: huang ep. Int J Radiat Oncol Biol Phys. 2024 Feb 29:S0360-3016(24)00323-7. doi: 10.1016/j.ijrobp.2024.02.014. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 38428681 Free article.
107 results